Stay current
Showing 0 of 1 items
This recent study concluded that commonly prescribed medications do not appear to alter the efficacy of immune checkpoint inhibitors in stage IV NSCLC, and advises previous associations seen in literature may be due to unmeasured confounding. Please see the attached trial for full details.
This content is available exclusively to MetroDIS subscribers. Unlock full access to all articles, resources, and tools with a subscription.
